Humacyte (NASDAQ:HUMA) Stock Price Expected to Rise, HC Wainwright Analyst Says

Humacyte (NASDAQ:HUMA) had its price target hoisted by research analysts at HC Wainwright from $6.00 to $12.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 127.27% from the stock’s current price.

A number of other research analysts have also commented on the stock. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the company a “neutral” rating in a research report on Friday, October 18th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. TD Cowen restated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. BTIG Research reiterated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. Finally, EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $11.00.

Humacyte Stock Performance

HUMA stock traded up $0.21 during midday trading on Tuesday, reaching $5.28. 279,079 shares of the company’s stock traded hands, compared to its average volume of 2,327,521. The company has a 50-day moving average price of $5.54 and a two-hundred day moving average price of $6.11. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41. Humacyte has a 52 week low of $2.08 and a 52 week high of $9.97. The firm has a market capitalization of $630.17 million, a PE ratio of -4.20 and a beta of 1.47.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, equities analysts anticipate that Humacyte will post -1.09 EPS for the current year.

Insiders Place Their Bets

In other Humacyte news, CEO Laura E. Niklason sold 277,090 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total value of $1,792,772.30. Following the completion of the sale, the chief executive officer now directly owns 4,029,374 shares of the company’s stock, valued at $26,070,049.78. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Laura E. Niklason sold 157,704 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $5.42, for a total transaction of $854,755.68. Following the completion of the transaction, the chief executive officer now directly owns 3,519,558 shares of the company’s stock, valued at approximately $19,076,004.36. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Laura E. Niklason sold 277,090 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the transaction, the chief executive officer now directly owns 4,029,374 shares of the company’s stock, valued at approximately $26,070,049.78. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,084,153 shares of company stock valued at $6,869,996 over the last three months. Insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Several institutional investors and hedge funds have recently bought and sold shares of HUMA. Millennium Management LLC lifted its holdings in Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after buying an additional 1,334,641 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Humacyte by 28.7% during the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after purchasing an additional 896,415 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after purchasing an additional 524,600 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Humacyte by 3,301.5% during the second quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after purchasing an additional 450,031 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C purchased a new position in shares of Humacyte during the second quarter valued at approximately $1,550,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.